 |
|
Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen Activator
Kara Z. Bambauer, PhD;
S. Claiborne Johnston, MD, PhD;
Derek E. Bambauer, JD;
Justin A. Zivin, MD, PhD
Arch Neurol. 2006;63:661-664.
Despite the US Food and Drug Administration's approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians' perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.
Author Affiliations: Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass (Dr K. Bambauer); Department of Neurology, University of California, San Francisco (Dr Johnston); Berkman Center for Internet & Society, Harvard Law School, Cambridge, Mass (Dr D. Bambauer); Department of Neurology, University of California San Diego, La Jolla (Dr Zivin).
RELATED LETTERS
Nonstroke treatment.
Arch Neurol. ;63():1506-1506.
FULL TEXT
Nonstroke Treatment--Reply
, , , and
Arch Neurol. ;63():1506-1507.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Telemedicine for acute stroke: When virtual is as good as reality
Levine and McConnochie
Neurology 2007;69:819-820.
FULL TEXT
New Approaches to Clinical Trials in Neuroprotection: Introduction
Goldberg
Stroke 2007;38:789-790.
FULL TEXT
November 14 Highlight and Commentary: Eliminating delay in rt-PA administration
Neurology 2006;67:1533-1533.
FULL TEXT
Nonstroke treatment.
Landau
Arch Neurol 2006;63:1506-1506.
FULL TEXT
Stroke Thrombolysis: Slow Progress
Caplan
Circulation 2006;114:187-190.
FULL TEXT
|
